Partial cystectomy with chemo for bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether removing part of the bladder (partial cystectomy) along with standard chemotherapy or immunotherapy before surgery is effective for people with a specific type of bladder cancer that hasn't spread beyond the bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bladder cancer called urothelial carcinoma that has grown into the muscle layer but not spread outside the bladder.
- You have one tumor or a few small tumors that can be completely removed with partial cystectomy, and the largest tumor is 5 cm or smaller.
- You are in good overall health (able to perform daily activities) and your kidney, liver, and blood counts are within normal limits.
- You have not had previous treatment for muscle-invasive bladder cancer.
- You do not have cancer spread to lymph nodes or distant organs, or certain other bladder conditions like hydronephrosis or carcinoma in situ.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding chemotherapy and immunotherapy along with targeted pelvic radiation after bladder tumor surgery can reduce bladder cancer returning or spreading. It focuses on people with non-metastatic, muscle-invasive urothelial bladder cancer.
This trial checks if a DNA blood test can help decide who needs extra chemo after bladder or upper urinary tract cancer surgery. It tests whether watching for cancer DNA in the blood can match patients to the right treatment.
This trial compares two main treatments for muscle-invasive bladder cancer: radical cystectomy (surgery to remove the bladder) and a combination of chemotherapy and radiation (chemo-radiation). The goal is to see which approach is better for patients whose cancer has not spread widely.
This trial tests whether using a patient's own tumor cells in lab-made clusters (PTCs) can help guide chemotherapy before bladder removal surgery for muscle-invasive bladder cancer. If you qualify, you'll receive personalized treatment followed by surgery.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (etoposide and cisplatin) given before surgery for a rare, aggressive type of bladder cancer called neuroendocrine carcinoma. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a dense schedule of two chemotherapy drugs (gemcitabine and cisplatin) given before bladder removal surgery. It aims to shrink the tumor and improve outcomes for people with bladder cancer that has grown into the muscle layer.
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.